Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BVAC-E6E7 in HPV 16/18 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06797986Phase 2Recruiting
- Sponsor
- Cellid Co., Ltd.
- Start
- Feb 2026
- Primary completion
- Mar 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of BVAC-E6E7 in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Cellid Co., Ltd. Primary endpoints: Dose-Limiting Toxicity, Objective Response Rate at 18 months and 4 more. Started Feb 2026; status: recruiting.
02
Drugs
BVAC-E6E7
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06797986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797986.